# 24 Patients. One Number. Allogene's Whole Future. - Date: 2026-03-26 - Category: Biotech & Life Sciences Allogene Therapeutics is about to bet its entire future on twelve people in each arm. In April 2026, the South San Francisco company will unblind a 24-patient interim snapshot from its ALPHA3 trial, split evenly between patients receiving cemacabtagene ansegedleucel — its off-the-shelf anti-CD19... ---